Table S1. Ongoing studies on combination of ICIs and target therapy in SCLC.
| ICIs | Other therapies | Target | Clinical trial | Phase | Stage | Status | Estimated Study Completion | Primary outcome measures |
|---|---|---|---|---|---|---|---|---|
| Anti-angiogenic agents | ||||||||
| Nivolumab | Anlotinib (AL3818) | VEGFR, FGFR, PDGFR, c-kit | NCT04165330 | Phase I/II | Unknown | Recruiting | 31-Dec-22 | ORR |
| Sintilimab | Anlotinib (AL3818) | VEGFR, FGFR, PDGFR, c-kit | NCT04055792 | Phase II | Unknown | Recruiting | 1-Mar-22 | PFS |
| Nivolumab | Vorolanib (X-82) | VEGFR/PDGFR | NCT03583086 | Phase I/II | Stage IV | Recruiting | Jul-24 | RP2D, Phase II best response |
| Nivolumab + Ipilimumab | XL184 (cabozantinib) | MET, VEGFR 2, AXL, ROS1, RET | NCT04079712 | Phase II | Unknown | Not yet recruiting | 17-Jul-22 | Overall response rate |
| Durvalumab | Bevacizumab | VEGF-A | NCT02734004 | Phase I/II | Unknown | Recruiting | 5-Aug-22 | DCR, ORR |
| Cyclin-dependent protein kinase inhibitors | ||||||||
| Atezolizumab | Trilaciclib | CDK4/6 | NCT03041311 | Phase II | ES | Active, not recruiting | May-20 | Chemotherapy-induced myelosuppression |
| Arginase and its inhibitor | ||||||||
| Pembrolizumab | Pegzilarginase | Arginase 1 | NCT03371979 | Phase I/II | Unknown | Active, not recruiting | Dec-20 | TEAEs, ORR |
| Pembrolizumab + Epacadostat | INCB001158 | Arginase | NCT03361228 | Phase I/II | Unknown | Completed | 30-Mar-19 | TEAEs, ORR |
| DNA damage response drugs | ||||||||
| Nivolumab | Rucaparib | PARP | NCT03958045 | Phase II | Stage IV | Recruiting | Jul-24 | PFS |
| Pembrolizumab | Amrubicin | Top 2 | NCT03253068 | Phase II | ES | Recruiting | 31-Aug-20 | Overall response rate |
| Pembrolizumab | ZN-c3 | WEE1 | NCT04158336 | Phase I/II | Unknown | Recruiting | Aug-23 | MTD, RP2D, ORR |
| Atezolizumab | PM01183 | Trans-activated transcription | NCT04253145 | Phase I | Unknown | Recruiting | Feb-22 | MTD, RD |
| Notch pathway inhibitors | ||||||||
| Pembrolizumab | AMG-757 | DLL3 | NCT03319940 | Phase I | Unknown | Recruiting | 4-Aug-23 | DLTs, TEAEs, significant changes |
| Nivolumab + Ipilimumab | Rovalpituzumab tesirine | DLL3 | NCT03026166 | Phase I/II | Unknown | Completed | 3-Jul-19 | CBR, DOR, ORR, PFS, OS |
| KRAS pathway inhibitors | ||||||||
| Nivolumab + Ipilimumab | Plinabulin | Tubulin polymerization | NCT03575793 | Phase I/II | ES | Recruiting | Sep-22 | MTD, PFS |
| LSD1 inhibitors | ||||||||
| Nivolumab | CC-90011 | LSD1 | NCT03850067 | Phase I/II | ES | Recruiting | 30-Sep-22 | DLT, MTD, AEs |
| Nivolumab | INCB059872 | LSD1 | NCT02712905 | Phase I/II | Unknown | Recruiting | 14-Dec-21 | AEs, RD |
| LXR inhibitors | ||||||||
| Docetaxel | RGX-104 | LXR | NCT02922764 | Phase I | Unknown | Recruiting | Mar-21 | MTD, Overall response rate, PFS, TEAEs |
ICIs, immune checkpoint inhibitors; OS, overall survival; PFS, progression-free survival; LS, limited stage; ES, extensive stage; VEGFR, endothelial growth factor receptor, FGFR, fibroblast growth factor receptor, PDGFR, platelet-derived growth factor receptors; LDS-1,lysine-specific demethylase 1; LXR, liver-X nuclear hormone receptor; KARS, Kirsten rat sarcoma viral oncogene homolog; PARP, poly (ADP-ribose) polymerase; Top 2, topoisomerase II; RP2D, recommended Phase II dose; DOR, duration of response; RD, recommended dose; AEs, adverse events; DCR, disease control rate; DLTs, dose-limiting toxicities; SAEs, serious adverse events; MTD, maximum tolerated dose; ORR, objective response rate; RR, response rate; TEAEs, treatment-emergent adverse events; CBR, clinical benefit rate.